There are already some add-on applets available in the COSMIC app store, such as both minimal and full-featured Start-menu ...

The ending is the main attraction of Tarkov 1.0, finally letting players experience the full story and make their way out of Tarkov in an exciting finale on a new map. Terminal is the final roadblock ...

Forbes contributors publish independent expert analyses and insights. Mike Stubbs covers esports, competitive games and the creator economy. Escape From Tarkov has officially launched with the 1.0 ...

Dominik Bošnjak is a freelance writer from Croatia. He has been writing about games for as long as he can remember and began doing so professionally circa 2010. If he was forced to pick a favorite ...

Almost exactly 10 years ago, a remarkable thing happened in a conference hall on the outskirts of Paris: After years of bitter negotiations, the leaders of nearly every country agreed to try to slow ...

Things are about to get messy for free, over-the-air TV. This week, the Federal Communications Commission (FCC) passed a notice of proposed rulemaking that’s designed to allow broadcast TV stations to ...

Changes in the vaccine advisory process in the United States have disrupted immunization guidance, which reinforces the need for independent evidence review to inform decisions regarding immunization ...

Microsoft today announced the first stable release of Windows ML, its AI inferencing runtime for Windows 11. Windows ML (Windows Machine Learning) is optimized for inferencing on-device AI models, ...

As a diehard enthusiast of video games, Ediz Guner has been attentively following the ebbs and flows of the gaming industry for a long period of time. This, coupled with his hobby of extensively ...

GameSpot may get a commission from retail offers. Palworld developer Pocketpair has announced that the game will leave early access and launch its 1.0 version in 2026. Additionally, the studio teased ...

Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, ...